BlinkLab Targeting Opportunities Beyond Flagship Autism Program

MT Newswires Live

07/14

BlinkLab (ASX:BB1) is expanding its study portfolio to evaluate its smartphone-based neurometric platform across additional neurological and psychiatric conditions beyond the company's flagship autism diagnostic program, according to a Tuesday filing with the Australian bourse.

The company said it has 10 ongoing clinical development programs aimed at validating new applications, establishing research collaborations, and identifying new commercial opportunities. These include a program for pediatric attention-deficit/hyperactivity disorder, early dementia detection, and spinocerebellar ataxia.

BlinkLab expects to deliver readouts from five programs this year, followed by five additional readouts in 2027, per the filing.

The company is also targeting a US Food and Drug Administration submission for its BlinkLab Dx1 diagnostic product by the end of the year.

BlinkLab's shares fell past 2% in recent Tuesday trade.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2651129040"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2651129040\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2651129040?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-14 12:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651129040","market":"sh","top_or_hot":-1,"title":"BlinkLab Targeting Opportunities Beyond Flagship Autism Program","media":"MT Newswires Live","content":"<html><body><p> BlinkLab (ASX:BB1) is expanding its study portfolio to evaluate its smartphone-based neurometric platform across additional neurological and psychiatric conditions beyond the company's flagship autism diagnostic program, according to a Tuesday filing with the Australian bourse.</p><p>The company said it has 10 ongoing clinical development programs aimed at validating new applications, establishing research collaborations, and identifying new commercial opportunities. These include a program for pediatric attention-deficit/hyperactivity disorder, early dementia detection, and spinocerebellar ataxia.</p><p>BlinkLab expects to deliver readouts from five programs this year, followed by five additional readouts in 2027, per the filing.</p><p>The company is also targeting a US Food and Drug Administration submission for its BlinkLab Dx1 diagnostic product by the end of the year.</p><p>BlinkLab's shares fell past 2% in recent Tuesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BlinkLab Targeting Opportunities Beyond Flagship Autism Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBlinkLab Targeting Opportunities Beyond Flagship Autism Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-14 12:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> BlinkLab (ASX:BB1) is expanding its study portfolio to evaluate its smartphone-based neurometric platform across additional neurological and psychiatric conditions beyond the company's flagship autism diagnostic program, according to a Tuesday filing with the Australian bourse.</p><p>The company said it has 10 ongoing clinical development programs aimed at validating new applications, establishing research collaborations, and identifying new commercial opportunities. These include a program for pediatric attention-deficit/hyperactivity disorder, early dementia detection, and spinocerebellar ataxia.</p><p>BlinkLab expects to deliver readouts from five programs this year, followed by five additional readouts in 2027, per the filing.</p><p>The company is also targeting a US Food and Drug Administration submission for its BlinkLab Dx1 diagnostic product by the end of the year.</p><p>BlinkLab's shares fell past 2% in recent Tuesday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7094","symbol_name":"医疗保健技术","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2651129040","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651129040","pubTimestamp":1784003738,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BlinkLab (ASX:BB1) is expanding its study portfolio to evaluate its smartphone-based neurometric platform across additional neurological and psychiatric conditions beyond the company's flagship autism","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7094":"医疗保健技术","BB1.AU":"Blinklab Ltd"},"translate_title":"BlinkLab 瞄准自闭症旗舰项目之外的机会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BB1.AU":1},"content_text":"BlinkLab (ASX:BB1) is expanding its study portfolio to evaluate its smartphone-based neurometric platform across additional neurological and psychiatric conditions beyond the company's flagship autism diagnostic program, according to a Tuesday filing with the Australian bourse.The company said it has 10 ongoing clinical development programs aimed at validating new applications, establishing research collaborations, and identifying new commercial opportunities. These include a program for pediatric attention-deficit/hyperactivity disorder, early dementia detection, and spinocerebellar ataxia.BlinkLab expects to deliver readouts from five programs this year, followed by five additional readouts in 2027, per the filing.The company is also targeting a US Food and Drug Administration submission for its BlinkLab Dx1 diagnostic product by the end of the year.BlinkLab's shares fell past 2% in recent Tuesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}